Cyclacel Pharmaceuticals (CYCC) has released an update to notify the public and investors about its officers.
Mark H. Kirschbaum, M.D. was terminated from his position as Chief Medical Officer at Cyclacel Pharmaceuticals, Inc. on January 25, 2024, with immediate effect. He retains the option to continue his health insurance benefits under COBRA, otherwise, his benefits will cease on January 31, 2024. Dr. Kirschbaum will not receive any severance benefits upon his employment termination.
For further insights into CYCC corporate activity, check out TipRanks’ Insiders Trading Activity page.
For a comprehensive understanding of the announcement, you can read the full document here.
